Medifast

Medifast, Inc. engages in the provision of healthy living products and programs. It offers the OPTAVIA brand, a lifestyle solution centered on developing new healthy habits through smaller, foundational changes called micro-habits. The firm’s product line includes bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. The company was founded by William Vitale in 1981 and is headquartered in Baltimore, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Medifast reports Q4 revenue decline, focuses on cost management

Medifast's Q4 2022 performance saw revenue decline but strong cost management and cash generation.
Challenges include revenue outlook for Q1 2023 and competitive landscape in weight loss and coaching markets.
Opportunities lie in capital allocation strategies, maintaining shareholder value, and adapting to market trends.
Overall, Medifast remains focused on long-term growth, financial stability, and delivering on its mission.

Medifast surpasses Q1 expectations, eyes growth amid operational tweaks

Medifast's Q1 2023 performance exceeded expectations, with a focus on revenue growth and cost control measures.
Despite challenges like decreased active coaches, the company is well-positioned with a strong financial standing and growth initiatives.
Opportunities in customer acquisition, cost-saving efforts, market expansion, and innovative solutions pave the way for future success.
Guidance for Q2 2023 reflects a strategic approach to balancing growth and profitability amidst market dynamics and operational changes.

Medifast reports Q2 revenue decline, eyes sustainable growth strategies

Medifast navigated challenges in Q2 2023 with improved operating margin and strategic market exits.
The company's focus on new growth initiatives and cost-saving measures reflects adaptability to market dynamics.
While facing revenue declines and competitive pressures, Medifast aims for sustainable growth with clear targets.
Exploration of medically supported weight loss solutions and new product lines offer avenues for future expansion.

Medifast reports resilient Q3 performance, eyes growth through diversification

Medifast's Q3 performance reflects resilience amid revenue decline, with a focus on operational efficiency and financial strength. While facing challenges in revenue and expense management, the company remains agile and proactive in exploring growth opportunities through market expansion and social responsibility initiatives.

Medifast transitions to health and wellness focus amidst revenue challenges

Medifast is navigating challenges in customer acquisition and macro factors while focusing on becoming a diversified health and wellness company.
The company's strategic collaboration with Life MD and new product offerings position it for growth.
While Q4 2023 saw a revenue decrease, Medifast's improved gross profit margin and cost-saving initiatives demonstrate operational efficiency.
Investors should monitor the impact of increased marketing spending on operating margin and EPS in the coming years.

Medifast faces revenue decline due to weight loss medication trends

Medifast's Q1 2024 performance reflects challenges in revenue and income, driven by difficulties in customer acquisition amidst weight loss medication trends.
Despite the decline, the company demonstrated operational efficiency with improved gross profit margins and cost management.
Investments in marketing and collaborations present opportunities for future growth and market expansion, signaling a strategic focus on long-term success.
Navigating market challenges while capitalizing on opportunities will be crucial for Medifast's resilience and competitiveness in the weight loss industry.

Medifast reports Q2 losses, focuses on growth strategies and cost management

Medifast's Q2 2024 performance reflects a challenging period marked by revenue and profit declines, offset by margin improvements and cost reductions.
The company's strategic initiatives aim to drive long-term growth and enhance operational efficiency amidst macroeconomic headwinds and lower coach productivity.
While facing financial setbacks, Medifast's focus on targeted advertising, product diversification, and cost management signifies a proactive stance towards future recovery and growth.

Medifast adapts to industry changes with tailored programs and innovations

Medifast's Q3 2024 performance reflected revenue and net income declines, highlighting challenges in the weight loss industry.
Despite these challenges, the company's strategic focus on tailored programs, strong financial position, and new product launches indicate a proactive approach to addressing market dynamics.
Opportunities in clinical studies, new product launches, and financial strength position Medifast for potential growth and market expansion in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Medifast, Inc. engages in the provision of healthy living products and programs. It offers the OPTAVIA brand, a lifestyle solution centered on developing new healthy habits through smaller, foundational changes called micro-habits. The firm's product line includes bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. The company was founded by William Vitale in 1981 and is headquartered in Baltimore, MD.

Medifast (MED) possesses solid growth attributes, which could help it handily outperform the market.

Medifast (MED) is an Incredible Growth Stock: 3 Reasons Why

Crocs

iRobot

Sprouts Farmers Markets

Meridian Bioscience

Crocs (CROX), iRobot (IRBT), Sprouts Farmers Market (SFM), Meridian Bioscience (VIVO) & MEDIFAST (MED) are the top five companies boasting solid efficiency levels at present.

5 Must-Buy Efficient Stocks to Make Your Portfolio Stand Out

Medifast's (MED) fourth-quarter 2020 results reflect strong earnings and sales growth. Robust OPTAVIA performance, courtesy of a rise in active earning coaches, fueled results.

Medifast (MED) Q4 Earnings Match Estimates, Sales Surge Y/Y

Medifast, Inc. (MED) CEO Dan Chard on Q4 2020 Results - Earnings Call Transcript

Medifast's (MED) fourth-quarter 2020 results are likely to reflect strength in OPTAVIA, thanks to consumers' growing inclination toward health and wellness.

Medifast (MED) Lined Up for Q4 Earnings: Key Things to Note

Celsius Holdings

Hain Celestial Group

Target

Although retailers have been struggling, grocery stocks like Target Corporation (TGT) and The Hain Celestial Group, Inc. (HAIN) have been benefiting since the coronavirus outbreak.

E-commerce Drives Grocery Sales in January: 4 Stocks to Buy

B&G Foods

United Natural Foods

Several food companies are gaining on higher at-home consumption amid the pandemic. Also, focus on innovation and other brand-building efforts has been backing growth for B&G Foods (BGS), Hain Celestial (HAIN), Medifast (MED) and United Natural (UNFI).

4 Food Stocks Up More Than 50% in 2020 With Room to Grow

Big Lots

Nu Skin Enterprises

SpartanNash

Weis Markets

According to the All-in-one Screener, a Premium feature of GuruFocus, five stocks with high financial strength and good dividend yields that have outperformed the Standard & Poor's 500 Index in 2020 are Medifast Inc. (NYSE:MED), Weis Markets Inc. (NYSE:WMK), Nu Skin Enterprises Inc. (NYSE:NUS), Big Lots Inc. (NYSE:BIG) and SpartinNash Co. (NASDAQ:SPTN).

5 Dividend Stocks to Consider for 2021

CareDx

CrowdStrike

MACOM Technology Solutions Holdings

Zscaler

Investing in stocks which have outpaced the market in 2020, defying the impacts of the COVID-19 outbreak, and have the potential for greater returns in 2021 is advisable.

5 Stocks With Unstoppable Growth to Buy in 2021

BALTIMORE, Dec. 29, 2020 /PRNewswire/ -- Medifast, Inc. (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTAVIA®, announced today that Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chief Financial Officer, will present...

Medifast, Inc. to Present at the 23rd Annual ICR Conference

Is (MED) Outperforming Other Consumer Staples Stocks This Year?

Is MEDIFAST INC (MED) Outperforming Other Consumer Staples Stocks This Year?

Medifast (MED) has been benefiting from strength in OPTAVIA along with a focus on core growth strategies even amid the pandemic.

Here's Why Medifast (MED) is Likely to Sustain Solid Run in 2021

BALTIMORE, Dec. 14, 2020 /PRNewswire/ -- Medifast, Inc. (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTAVIA®, announced that Non- Executive Chairman of the Board, Michael MacDonald, has stepped down from the role. At its regularly...

Michael MacDonald to Step Down as Non-Executive Chairman of Medifast's Board of Directors; Chief Executive Officer Dan Chard Named Chairman

Best Buy

Herbalife

Lowe's

Lam Research

Thermo Fisher Scientific

Growth names have been at the forefront of this new COVID world, and have kept society not only afloat, but growing and transitioning to this new normal. Nobody knows exactly what the future will hold, but our AI algorithms have identified standout growth stocks via our rating system.

Top Growth Stocks For December

Medifast (MED) reported earnings 30 days ago. What's next for the stock?

Medifast (MED) Up 30.4% Since Last Earnings Report: Can It Continue?

Medifast (MED) has been gaining on robust performance of OPTAVIA. Also, the company has certain planned investments for growth, though they are likely to affect margins.

Medifast (MED) Up More Than 75% YTD: Will Momentum Stay?

Splash Beverage Group

Weightwatchers International Inc.

The functional foods market saw sales top $267 billion in February of this year on a global basis, with sales in the US reaching $63 billion, according to Euromonitor 2020.

The Health Food Space Keeps Roaring (OTC US: SBEV) ($MED) ($WW)

Planet Fitness

Healthy Living Stocks for the Win (NASDAQ: WW) (NYSE: PLNT) (OTC: SBEV) (NYSE: MED)

Medifast's (MED) third-quarter 2020 results reflect increased earnings and sales. Robust OPTAVIA performance, courtesy of rise in active earning coaches, fuels results.

Medifast (MED) Q3 Earnings Surpass Estimates, Increase Y/Y

Medifast, Inc. (MED) CEO Dan Chard on Q3 2020 Results - Earnings Call Transcript

Medifast (MED) delivered earnings and revenue surprises of 16.87% and 10.20%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Medifast (MED) Q3 Earnings and Revenues Top Estimates

Medifast, Inc. (MED) CEO Dan Chard on Q3 2020 Results - Quick Version Earnings Call Transcript

BALTIMORE, Nov. 2, 2020 /PRNewswire/ -- Medifast, Inc. (NYSE: MED), the company behind one of the fastest growing health and wellness communities, OPTAVIA®, which offers Lifelong Transformation, One Healthy Habit at a Time®, today announced it was ranked second on FORTUNE© Magazine's list...

Medifast, Inc. Ranks Number Two on FORTUNE's Annual 100 Fastest-Growing Companies List

The large amount of overweight adults in the United States and other regions provides a significant market for Medifast's growth. Medifast has positive revenue and earnings growth momentum that can continue in future years.

Medifast: Dividend Stock With Strong Future Growth Potential

Medifast's (MED) third-quarter results are likely to reflect gains from consumers' increased inclination toward health products amid the pandemic. However, high costs are a concern.

News for Medifast Stock (MED)